Details of the Drug Reposition

General Information of This Drug (ID: DMIJGT9)

Drug Name
INCB24360   DMIJGT9
Synonyms Epacadostat
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urothelial carcinoma DISRTNTN 2C92.0 Phase 3 [1]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [2]
Melanoma DIS1RRCY 2C30 Phase 2 [3]
------------------------------------------------------------------------------------
8 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 1 [4]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [3]
B-cell lymphoma DISIH1YQ 2A86 Phase 1 [3]
Colorectal cancer DISNH7P9 2B91.Z Phase 1 [3]
Lung cancer DISCM4YA 2C25.0 Phase 1 [3]
Merkel cell carcinoma DISDJJ4U 2C34 Phase 1 [3]
Ovarian cancer DISZJHAP 2C73 Phase 1 [3]
Head and neck cancer DISBPSQZ 2D42 Phase 1 [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)

References

1 ClinicalTrials.gov (NCT03361865) Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307). U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8221).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)